Physician profile

Weems Pennington

Cardiovascular Disease · Aiken, SC

NPI 1215027263

$3,982.39

in general payments reported to CMS, 2019-2025

39 companies · $664 in 2025

The $664 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,913.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,216.37 2019-2025 Watchman Flx, Watchman Access System, Cds Broad Portfolio Offering
Novartis Pharmaceuticals Corporation $331.82 2019-2025
Pfizer INC. $276.12 2019-2025
Abbott Laboratories $260.76 2019-2025 Diamondback Coronary, Pressurewire, Aveir
Abiomed $165.68 2024-2025
E.R. Squibb & Sons, L.L.C. $152.49 2021-2025 Camzyos
Astrazeneca Pharmaceuticals LP $148.56 2019-2022
Cardiovascular Systems INC. $130.91 2019-2023 Diamondback Coronary
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $124.69 2023-2025 Lifevest
Amgen INC. $123.56 2019-2020
Inari Medical, INC. $110.42 2022-2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Medtronic, INC. $109.46 2022-2025 Micra, Cobalt Dr Mri Surescan, Valiant Captivia
Sanofi-Aventis U.S. LLC $77.42 2019
Janssen Pharmaceuticals, INC $62.43 2019-2023 Xarelto
Astellas Pharma US INC $55.55 2020
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Stryker Corporation $53.58 2025 Flowtriever, Clottriever Bold Catheter
Kiniksa Pharmaceuticals, LTD. $51.34 2022-2023 Arcalyst
Penumbra, INC. $45.62 2025 Indigo System
Daiichi Sankyo INC. $44.02 2019-2025 Injectafer
Novo Nordisk INC $40.44 2023-2025 Wegovy, Ozempic, Rybelsus
Veryan Medical Incorporated $37.55 2023 Biomimics 3d Vascular Stent System
Kiniksa Pharmaceuticals International, Plc $34.69 2024 Arcalyst
Shockwave Medical, INC $32.02 2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Medtronic Vascular, INC. $25.99 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $25.80 2019
Arbor Pharmaceuticals, INC. $24.82 2019-2020
W. L. Gore & Associates, INC. $24.62 2025 Gore Viabahn Vbx Balloon Expandable Endo
Vital Connect, INC $20.70 2022
Cardiva Medical, INC. $19.64 2023 Cardiva Vascade Mvp Vvcs 6-12f
Chiesi USA, INC. $17.95 2019
Biotronik INC. $17.07 2022
Getinge USA Sales, LLC $16.67 2020
Bayer Healthcare Pharmaceuticals INC. $16.63 2024
Solventum Corporation $16.58 2025 Activ.A.C., Promogran Prisma
Lundbeck LLC $15.39 2019
Baxter Healthcare $15.05 2023 Hillrom - Carnation Ambulatory Monitor
Itamar Medical INC $14.76 2021
Amarin Pharma, INC. $13.71 2019
Merck Sharp & Dohme LLC $11.51 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Weems Pennington

$3,982.39

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $664 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/9315/weems-pennington

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.